Time course proteomic profiling of human myocardial infarction plasma samples: An approach to new biomarker discovery
| Contribuinte(s) |
UNIVERSIDADE DE SÃO PAULO |
|---|---|
| Data(s) |
19/10/2012
19/10/2012
2011
|
| Resumo |
Background: The aim of this study was to identify novel candidate biomarker proteins differentially expressed in the plasma of patients with early stage acute myocardial infarction (AMI) using SELDI-TOF-MS as a high throughput screening technology. Methods: Ten individuals with recent acute ischemic-type chest pain (< 12 h duration) and ST-segment elevation AMI (1STEMI) and after a second AMI (2STEMI) were selected. Blood samples were drawn at six times after STEMI diagnosis. The first stage (T(0)) was in Emergency Unit before receiving any medication, the second was just after primary angioplasty (T(2)), and the next four stages occurred at 12 h intervals after T(0). Individuals (n = 7) with similar risk factors for cardiovascular disease and normal ergometric test were selected as a control group (CG). Plasma proteomic profiling analysis was performed using the top-down (i.e. intact proteins) SELDI-TOF-MS, after processing in a Multiple Affinity Removal Spin Cartridge System (Agilent). Results: Compared with the CG, the 1STEMI group exhibited 510 differentially expressed protein peaks in the first 48 h after the AMI (p < 0.05). The 2STEMI group, had similar to 85% fewer differently expressed protein peaks than those without previous history of AMI (76, p < 0.05). Among the 16 differentially-regulated protein peaks common to both STEMI cohorts (compared with the CG at T(0)), 6 peaks were persistently down-regulated at more than one time-stage, and also were inversed correlated with serum protein markers (cTnI, CK and CKMB) during 48 h-period after IAM. Conclusions: Proteomic analysis by SELDI-TOF-MS technology combined with bioinformatics tools demonstrated differential expression during a 48 h time course suggests a potential role of some of these proteins as biomarkers for the very early stages of AMI, as well as for monitoring early cardiac ischemic recovery. (C) 2011 Elsevier B.V. All rights reserved. FAPESP[2006/03487-4] FAPESP, Sao Paulo, SP, Brazil CAPES, Brasilia, DF, Brazil CNPq, Brasilia, DF, Brazil |
| Identificador |
CLINICA CHIMICA ACTA, v.412, n.11/Dez, p.1086-1093, 2011 0009-8981 http://producao.usp.br/handle/BDPI/19551 10.1016/j.cca.2011.02.030 |
| Idioma(s) |
eng |
| Publicador |
ELSEVIER SCIENCE BV |
| Relação |
Clinica Chimica Acta |
| Direitos |
restrictedAccess Copyright ELSEVIER SCIENCE BV |
| Palavras-Chave | #Acute myocardial infarction #SELDI-TOF-MS #Biomarker #Proteomics #SELDI-TOF-MS #ACUTE CORONARY SYNDROME #CARDIOVASCULAR-DISEASE #INTERNATIONAL-SOCIETY #IDENTIFICATION #DIAGNOSIS #HYPERTENSION #MICROARRAY #EXPRESSION #PRINCIPLE #Medical Laboratory Technology |
| Tipo |
article original article publishedVersion |